@article{10.1371/journal.pcbi.1002817, doi = {10.1371/journal.pcbi.1002817}, author = {Karczewski, Konrad J. AND Daneshjou, Roxana AND Altman, Russ B.}, journal = {PLOS Computational Biology}, publisher = {Public Library of Science}, title = {Chapter 7: Pharmacogenomics}, year = {2012}, month = {12}, volume = {8}, url = {https://doi.org/10.1371/journal.pcbi.1002817}, pages = {1-18}, abstract = {There is great variation in drug-response phenotypes, and a “one size fits all” paradigm for drug delivery is flawed. Pharmacogenomics is the study of how human genetic information impacts drug response, and it aims to improve efficacy and reduced side effects. In this article, we provide an overview of pharmacogenetics, including pharmacokinetics (PK), pharmacodynamics (PD), gene and pathway interactions, and off-target effects. We describe methods for discovering genetic factors in drug response, including genome-wide association studies (GWAS), expression analysis, and other methods such as chemoinformatics and natural language processing (NLP). We cover the practical applications of pharmacogenomics both in the pharmaceutical industry and in a clinical setting. In drug discovery, pharmacogenomics can be used to aid lead identification, anticipate adverse events, and assist in drug repurposing efforts. Moreover, pharmacogenomic discoveries show promise as important elements of physician decision support. Finally, we consider the ethical, regulatory, and reimbursement challenges that remain for the clinical implementation of pharmacogenomics.}, number = {12}, }